<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823185</url>
  </required_header>
  <id_info>
    <org_study_id>STGUD005</org_study_id>
    <nct_id>NCT01823185</nct_id>
  </id_info>
  <brief_title>Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy</brief_title>
  <official_title>Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dammam University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Fahad Armed Forces Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dammam Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dammam University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary
      intervention (PCI) with stent implantation and during one year after PCI, to prevent
      atherothrombotic complications. However, clopidogrel is ineffective in certain patients due
      to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of
      clopidogrel. Therefore, the purpose of this study is to test these patients genetically at
      bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel
      ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight &lt;
      60kg) if they are carriers of the allele 2 or 3 of the mutated gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary
      intervention (PCI) with stent implantation and during one year after PCI, to prevent
      atherothrombotic complications. Clopidogrel is converted into its active metabolite by
      Cytochrome P2C19 (CYP2C19). However 30 % of the Saudi population is carrier of the non
      functional CYP2C19*2 or *3 alleles having an impaired CYP2C19 capacity, resulting in
      decreased effectiveness of Clopidogrel. These patients have a 42% higher risk for major
      cardiovascular events (MACE) compared to non carriers. Further 50 % of the MACE occurs in the
      first 48 hours. Therefore Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or
      5mg once daily if the patient older than 75 years or a body weight &lt; 60kg) whose actions are
      not dependent on conversion by CYP2C19 may be an alternative only in carriers of the non
      functional CYP2C19*2 or *3 alleles. This might be cost effective and prevent patients form
      MACE. Therefore the objective of this study is to assess the efficacy, complication free
      survival, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment
      strategy, using clopidogrel or prasugrel (or Ticlid). All participants will be followed for
      one year using follow up questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular event</measure>
    <time_frame>1 year</time_frame>
    <description>The primary end point is the number of patients who develop adverse major cardiovascular event which include recurrent myocardial infarction, non-fatal stroke, cardiovascular mortality, severe ischemia, major bleeding at 30days after PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Secondary efficacy endpoints are the number of patients who either died , died from cardiovascular death, from cerebrovascular death, developed recurrent MI, stent thrombosis, underwent urgent target vessel revascularization, developed stroke or combination of above</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Disease</condition>
  <condition>Vascular Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Ischemia</condition>
  <condition>Infarction</condition>
  <condition>Embolism</condition>
  <condition>Thrombosis</condition>
  <condition>Chest Pain</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor or prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight &lt; 60kg) according to local protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight &lt; 60kg) according to local protocol.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Clavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor or prasugrel</intervention_name>
    <description>ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight &lt; 60kg) according to local protocol.</description>
    <arm_group_label>Ticagrelor or prasugrel</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Prasuvas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Male &amp; female age 18-70 years

        Inclusion Criteria:

          -  Patient presents with acute myocardial infarction of more than 30 minutes and less
             than 12 hours

          -  Patient eligible for PCI

        Exclusion Criteria:

          -  Life expectancy of less than one year

          -  Previously Known genotype

          -  Receiving chemotherapy for malignancy

          -  On dialysis or receiving immunosuppressive therapy or have autoimmune disease

          -  Hepatic impairment

          -  History of bleeding diathesis

          -  Receiving vitamin K antagonist therapy

          -  Confirmed hypertension

          -  Out of normal range platelet count

          -  History of major surgery

          -  Severe trauma or fracture

          -  Pregnancy and lactation

          -  Concomitant use of simvastatin, cytochrome P450 3A4 inhibitors or inducers

          -  Hypersensitivity to clopidogrel or ticagrelor or prasugrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah M Al-Rubaish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imam Abdulrahman Bin Faisal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amein K Al-Ali, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Imam Abdulrahman Bin Faisal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amein K Al-Ali, PhD</last_name>
    <phone>+966505821693</phone>
    <email>ameinomran@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdullah M Al-Rubaish, MD</last_name>
    <phone>+966 505 874722</phone>
    <email>arubaish@ud.edu.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince Sultan Cardiac center</name>
      <address>
        <city>Al-Hasa</city>
        <zip>31982</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abdullah Alabdulgader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Fahd University Hospital</name>
      <address>
        <city>Al-Khobar</city>
        <zip>31441</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abdullah M Al-Rubaish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fahd A Al-Muhanna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Larbi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdullah Al-Shehri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akram Al-Khadra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amein Al-Ali, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Al-Mansory, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saud Al-Babtain Cardiac Center</name>
      <address>
        <city>Dammam</city>
        <zip>31463</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hamid Al-Omran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mustafa Al-Refaei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Najeeb Abdulhamid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shukry Mirza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yousef Alsabeet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Fahd Military Medical Complex</name>
      <address>
        <city>Dammam</city>
        <zip>31932</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Khalid Al-Fraiedi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Platelet aggregation inhibitor</keyword>
  <keyword>Dammam University</keyword>
  <keyword>King Fahd Hospital</keyword>
  <keyword>Purinergic P2 receptor Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Purinergic P2 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

